UTi Chairman Roger MacFarlane said he strongly recommended shareholders accept the offer.

Different lactobacilli strains show different results in the prevention of recurrent UTIs.

Additional clinical research is necessary to improve UTI prevention and care strategies.

But analysts also noted UTi's recent performance as a challenge for DSV.

However, UTIs are well tolerated and do not seem to modify outcome.